Biotech & AI drug discoverySTAT — Biotech

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which is being studied in more than 200 patients with advanced solid tumors, including metastatic pancreatic ductal adenocarcinoma. The reported findings remain early-stage.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-15T15:43:15+00:00

Published here2026-10-15T16:35:32+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/15/biotech-news-verastem-kras-inhibitor-shows-promise-in-pancreatic-cancer/

Original headline

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.